Other languages Vertex Pharmaceuticals Incorporated

Equities

VRTX

US92532F1003

Market Closed - Nasdaq Other stock markets 04:00:00 2024-05-28 pm EDT			5-day change	1st Jan Change
446.9 ^USD	-2.20%		+0.23%	+9.83%

May. 24	Vertex Pharmaceuticals Insider Sold Shares Worth $3,168,704, According to a Recent SEC Filing	MT
May. 22	Vertex Pharmaceuticals Insider Sold Shares Worth $6,795,294, According to a Recent SEC Filing	MT

Other languages

Unlock all the news on all businesses: Never miss an investment opportunity again!

100% Free Registration

Vertex Pharmaceuticals Insider Sold Shares Worth $3,168,704, According to a Recent SEC Filing	May. 24
Compañías que se deben tener muy en cuenta por técnico este viernes en Wall Street	May. 24
ETF de la semana: Los “utilities” desempeñan un papel en la aparición del AII	May. 23
Vertex Pharmaceuticals Insider Sold Shares Worth $6,795,294, According to a Recent SEC Filing	May. 22
ADDvise Group’s Axelerist Bags $1.4 Million Order for Medical, Lab Equipment	May. 21
Compañías que se deben tener muy en cuenta por técnico este lunes en Wall Street	May. 20
Valores destacados al cierre del mercado norteamericano	May. 20
Vertex Pharmaceuticals Incorporated completed the acquisition of Alpine Immune Sciences, Inc. from a group of shareholders.	May. 19
ETF de la semana: India y Brasil podrían despertar	May. 16
Vertex Pharmaceuticals Incorporated Appoints Jennifer Schneider as Independent Director	May. 15
Compañías que se deben tener muy en cuenta por técnico este lunes en Wall Street	May. 13
Alpine Immune Sciences, Vertex Pharmaceuticals Deal Crosses Another Milestone	May. 10
Compañías que se deben tener muy en cuenta por técnico este jueves en Wall Street	May. 09
EE.UU. - Valores a seguir en Wall Street (actualizado)	May. 07
RECOMENDACIONES DE LOS ANALISTAS EE.UU./UK : Nvidia, The Home Depot, Palantir, Target, Lowe's, Block, Rollins...	May. 07
Vertex Pharmaceuticals Q1 Non-GAAP EPS, Revenue Increase	May. 06
Vertex Pharmaceuticals Incorporated Reports Earnings Results for the First Quarter Ended March 31, 2024	May. 06
Vertex tops Q1 profit estimates on robust demand for cystic fibrosis treatments	May. 06
Vertex Pharmaceuticals Incorporated Re-Iterates Earnings Guidance for the Full Year 2024	May. 06
Equity Markets Higher as Traders Parse Fed Official's Remarks	May. 06

No results for this search

All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

Filters

Headlines

Vertex Pharmaceuticals Incorporated : Vertex and Crispr to market $2.2 million treatment for sickle cell disease

December 11, 2023 at 05:47 am EST